<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01703208</url>
  </required_header>
  <id_info>
    <org_study_id>3102-018</org_study_id>
    <secondary_id>2012-002414-39</secondary_id>
    <secondary_id>MK-3102-018</secondary_id>
    <nct_id>NCT01703208</nct_id>
  </id_info>
  <brief_title>A Study to Assess Cardiovascular Outcomes Following Treatment With Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (MK-3102-018)</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the cardiovascular (CV) safety profile of
      omarigliptin in participants with type 2 diabetes mellitus (T2DM). The primary hypothesis is
      that treatment with omarigliptin 25 mg once weekly is non-inferior to treatment with placebo
      and active comparators across the omarigliptin program with regard to the risk of developing
      a confirmed event in the primary CV composite endpoint.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial was amended to extend the length of the trial in order to meet FDA requirements for
      the post-approval assessment of cardiovascular (CV) safety. The trial now contains 2 time
      intervals: Period 1 and Period 2. Period 1 refers to the time interval up to this recent
      protocol amendment and Period 2, the time interval from this protocol amendment until the end
      of the study. Participants in Period 1 will be re-consented and continue into Period 2. If
      required, additional participants will be enrolled in Period 2. Stage 1 refers to the
      prefiling United States Food and Drug Administration (US FDA) requirement to rule out a 80%
      increased CV risk. Stage 2 refers to the US FDA post-marketing requirement to rule out a 30%
      increased CV risk. The Stage 1 assessment of CV risk occurred during Period 1 and was based
      on a meta-analysis of major adverse CV events (MACE) and unstable angina across the
      omarigliptin Phase 2/Phase 3 program. The Stage 2 assessment will be based on MACE in P018
      alone including CV events from both Period 1 and Period 2.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was terminated for business reasons and not due to any safety or efficacy concerns
    related to omarigliptin
  </why_stopped>
  <start_date type="Actual">October 5, 2012</start_date>
  <completion_date type="Actual">March 22, 2017</completion_date>
  <primary_completion_date type="Actual">May 13, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With MACE-plus (Confirmed Cardiovascular [CV]-Related Death, Nonfatal Myocardial Infarction [MI], Nonfatal Stroke, or Hospitalization Due to Unstable Angina)</measure>
    <time_frame>Up to 156 weeks</time_frame>
    <description>Participants with confirmed MACE-plus events (confirmed cardiovascular, CV-related death, nonfatal myocardial infarction [MI], nonfatal stroke, or hospitalization due to unstable angina). In the MK-3102-018 study, MACE plus events had a data cut-off date of April 15, 2015.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With an Event of MACE (Confirmed CV-Related Death, Fatal and Nonfatal MI, and Fatal and Nonfatal Stroke)</measure>
    <time_frame>Up to 179 weeks</time_frame>
    <description>Participants with an Event of MACE (confirmed cardiovascular, CV-related death, fatal and nonfatal myocardial infarction [MI], and fatal and nonfatal stroke).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With an Event Per 100 Person-Years for First Event of MACE (Confirmed CV-Related Death, Fatal and Nonfatal MI, and Fatal and Nonfatal Stroke)</measure>
    <time_frame>Up to 179 weeks</time_frame>
    <description>Participants with an event of MACE (confirmed cardiovascular, CV-related death, fatal and nonfatal myocardial infarction [MI], and fatal and nonfatal stroke). Person-years were calculated as the sum of all participants' follow-up time to first event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hemoglobin A1C (A1C) at Week 18</measure>
    <time_frame>Baseline and Week 18</time_frame>
    <description>A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). This change from baseline reflects the Week 18 A1C minus the Week 0 A1C.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in A1C at Week 18 in a Sub-Study of Participants Taking Insulin (With or Without Metformin)</measure>
    <time_frame>Baseline and Week 18</time_frame>
    <description>A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). This change from baseline reflects the Week 18 A1C minus the Week 0 A1C.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Experienced at Least One Adverse Event in a Sub-study of Participants Taking Insulin Excluding Data After Background Antihyperglycemic Agent (AHA) Change</measure>
    <time_frame>Up to Week 18</time_frame>
    <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Discontinued From Study Drug Due to an Adverse Event in a Sub-Study of Participants Taking Insulin Excluding Data After Background AHA Change</measure>
    <time_frame>Up to Week 18</time_frame>
    <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With an Event of CV-Related Death</measure>
    <time_frame>Up to 179 weeks</time_frame>
    <description>Participants with adjudicated and confirmed AEs of cardiovascular-related death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With an Event Per 100 Person-Years of CV-Related Death</measure>
    <time_frame>Up to 179 weeks</time_frame>
    <description>Participants with adjudicated and confirmed AEs of cardiovascular-related death. Person-years were calculated as the sum of all participants' follow-up time to event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With an Event of First MI (Fatal and Non-fatal)</measure>
    <time_frame>Up to 179 weeks</time_frame>
    <description>Participants with adjudicated and confirmed AEs of fatal and non-fatal MI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With an Event Per 100 Person-Years of First MI (Fatal and Non-fatal)</measure>
    <time_frame>Up to 179 weeks</time_frame>
    <description>Participants with adjudicated and confirmed AEs of fatal and non-fatal MI. Person-years were calculated as the sum of all participants' follow-up time to first event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With an Event of Stroke (Fatal and Non-fatal)</measure>
    <time_frame>Up to 179 weeks</time_frame>
    <description>Participants with adjudicated and confirmed AEs fatal and non-fatal stroke.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With an Event Per 100 Person-Years of First Stroke (Fatal and Non-fatal)</measure>
    <time_frame>Up to 179 weeks</time_frame>
    <description>Participants with adjudicated and confirmed AEs fatal and non-fatal stroke. Person-years were calculated as the sum of all participants' follow-up time to event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With an Event of All-Cause Death</measure>
    <time_frame>Up to 179 weeks</time_frame>
    <description>All-cause death was death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With an Event Per 100 Person-Years of the Event of All-Cause Death</measure>
    <time_frame>Up to 179 weeks</time_frame>
    <description>All-cause death was death for any cause. Person-years were calculated as the sum of all participants' follow-up time to event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in A1C at Week 142</measure>
    <time_frame>Baseline and Week 142</time_frame>
    <description>A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). This change from baseline reflects the Week 142 A1C minus the Week 0 A1C.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a Target A1C &lt;7.0 % (53 mmol/Mol) at 4 Months</measure>
    <time_frame>4 months</time_frame>
    <description>A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose (FPG) at 4 Months</measure>
    <time_frame>Baseline and 4 months</time_frame>
    <description>This change from baseline reflects the Month 4 FPG minus the Week 0 FPG.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Initiation of Long-Term Insulin Therapy in Participants Not Receiving Insulin at Baseline</measure>
    <time_frame>Up to 179 weeks</time_frame>
    <description>Long-term insulin therapy was defined as a continuous period of insulin use of more than 3 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Experienced at Least One Adverse Event</measure>
    <time_frame>Up to 234 weeks</time_frame>
    <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Discontinued From Study Drug Due to an Adverse Event</measure>
    <time_frame>Up to 212 weeks</time_frame>
    <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in FPG at Week 18 in a Sub-Study of Participants Taking Insulin</measure>
    <time_frame>Baseline and Week 18</time_frame>
    <description>This change from baseline reflects the Week 18 FPG minus the Week 0 FPG.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a Target A1C &lt;7.0 % (53 mmol/Mol) at Week 18 in a Sub-Study of Participants Taking Insulin</measure>
    <time_frame>18 weeks</time_frame>
    <description>A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Analysis was performed with multiple data imputation.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants With an Event of First Hospitalization for Heart Failure (Exploratory)</measure>
    <time_frame>Up to 179 weeks</time_frame>
    <description>Participants with adjudicated and confirmed events of first hospitalization for heart failure.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With an Event Per 100 Person-years of the Event of the First Hospitalization for Heart Failure (Exploratory)</measure>
    <time_frame>Up to 179 weeks</time_frame>
    <description>Participants with adjudicated and confirmed events of first hospitalization for heart failure. Person-years were calculated as the sum of all participants' follow-up time to event.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4202</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Omarigliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Omarigliptin (MK-3102) 25 mg capsule or tablet administered orally once weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo to omarigliptin capsule or tablet administered orally once weekly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omarigliptin</intervention_name>
    <description>Omarigliptin (MK-3102) 25 mg capsule or tablet administered orally once weekly</description>
    <arm_group_label>Omarigliptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo to omarigliptin capsule or tablet administered orally once weekly</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with type 2 diabetes mellitus

          -  Is on one of the following diabetes treatment regimens that is stable for at least 12
             weeks (except for pioglitazone for at least 16 weeks) and is within the associated A1C
             range for that treatment regimen:

               1. A1C &gt;= 6.5% and &lt;= 10.0% (&gt;=48 mmol/mol and &lt;=86 mmol/mol) on: (a) diet or
                  exercise alone (not on antihyperglycemic agent [AHA] for &gt;= 12 weeks) OR (b)
                  monotherapy with metformin (MF), pioglitazone (PIO) or an alpha-glucosidase
                  inhibitor (AGI) or a sodium-glucose cotransporter inhibitor (SGLT2i) OR (c) dual
                  combination therapy with MF, PIO, AGI or SGLT2i OR

               2. A1C &gt;= 7.0% and &lt;=10.0% (&gt;=53 mmol/mol and &lt;=86 mmol/mol) on (a) monotherapy with
                  a sulfonylurea or meglitinide OR (b) dual combination therapy with a sulfonylurea
                  or a meglitinide and MF, PIO, AGI, or SGLT2i OR

               3. A1C &gt;=7.0% and &lt;=10.0% (&gt;=53 mmol/mol and &lt;=86 mmol/mol) on one of the following
                  insulin regimens (with or without metformin): (a) basal insulin (e.g.; insulin
                  glargine, insulin detemir, NPH insulin, degludec) OR (b) prandial insulin (e.g.
                  regular, aspart, lispro, glulisine) OR (c) basal/prandial insulin regimen
                  consisting of multiple dose insulin injections of basal and prandial insulin or
                  the use of pre-mixed insulin (e.g., Novolog 70/30®, Novolin 70/30®, Humalog
                  75/25®, or Humulin 70/30®

          -  Pre-existing vascular disease (coronary artery disease, ischemic cerebrovascular
             disease, atherosclerotic peripheral artery disease)

          -  (1) Male; (2) female not of reproductive potential; or (3) female of reproductive
             potential who agrees to remain abstinent or use alone or in conjunction with their
             partner 2 methods of contraception to prevent pregnancy during the study and for 21
             days after the last dose of study drug.

        Exclusion Criteria:

          -  History of type 1 diabetes mellitus or a history of ketoacidosis

          -  Treated with rosiglitazone, a dipeptidyl peptidase-IV (DPP-4) inhibitor, or a
             glucagon-like peptide-1 (GLP-1) receptor agonist within 12 weeks prior to study
             participation or previously treated with omarigliptin

          -  On a weight loss program and is not in the maintenance phase or has been on a weight
             loss medication in the past 6 months or has undergone bariatric surgery within 12
             months prior to study participation

          -  Medical history of active liver disease (other than non-alcoholic hepatic steatosis),
             including chronic active hepatitis B or C, primary biliary cirrhosis, or symptomatic
             gallbladder disease

          -  Human immunodeficiency virus (HIV) as assessed by medical history

          -  New or worsening coronary heart disease, congestive heart failure, myocardial
             infarction, unstable angina, coronary artery intervention, stroke, or transient
             ischemic neurological disorder within the past 3 months

          -  History of malignancy &lt;=5 years prior to study participation, except for adequately
             treated basal cell or squamous cell skin cancer, or in situ cervical cancer

          -  Clinically important hematological disorder (such as aplastic anemia,
             myeloproliferative or myelodysplastic syndromes, thrombocytopenia)

          -  Pregnant or breast feeding, or is expecting to conceive or donate eggs during the
             trial, including 21 days following the last dose of study drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Croatia</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Lebanon</country>
    <country>Lithuania</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Gantz I, Chen M, Suryawanshi S, Ntabadde C, Shah S, O'Neill EA, Engel SS, Kaufman KD, Lai E. A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2017 Sep 11;16(1):112. doi: 10.1186/s12933-017-0593-8.</citation>
    <PMID>28893244</PMID>
  </results_reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2012</study_first_submitted>
  <study_first_submitted_qc>October 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2012</study_first_posted>
  <results_first_submitted>November 13, 2017</results_first_submitted>
  <results_first_submitted_qc>November 13, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 12, 2017</results_first_posted>
  <last_update_submitted>November 13, 2017</last_update_submitted>
  <last_update_submitted_qc>November 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 559 sites received IEC/IRB approval in 40 countries and 547 were shipped clinical supplies. Of the 559 sites, 525 screened at least 1 participant.
An insulin sub-study of MK-3102-018 was performed and included the sub-population of participants receiving ≥20 units/day of background insulin with or without metformin.</recruitment_details>
      <pre_assignment_details>On April 8, 2016, Merck &amp; Co. Inc. announced that it would not submit marketing applications for omarigliptin (MK-3102) in the US and Europe for business reasons only. Because of this decision, the MK-3102-018 study was terminated early on May 13, 2016. Due to delays in study close-out the Last-Participant-Last-Visit occurred on March 22, 2017.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Omarigliptin 25 mg</title>
          <description>Omarigliptin (MK-3102) 25 mg capsule or tablet administered orally once weekly</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Matching placebo to omarigliptin capsule or tablet administered once weekly.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2100"/>
                <participants group_id="P2" count="2102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="2092"/>
                <participants group_id="P2" count="2100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2100"/>
                <participants group_id="P2" count="2102"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="62"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-Compliance with Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Excluded Medication</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site Discontinued Study Participation</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive disease</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Terminated by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="1710"/>
                <participants group_id="P2" count="1716"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="205"/>
                <participants group_id="P2" count="209"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Technical Problems</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Omarigliptin 25 mg</title>
          <description>Omarigliptin (MK-3102) 25 mg capsule or tablet administered orally once weekly</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Matching placebo to omarigliptin capsule or tablet administered once weekly.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2100"/>
            <count group_id="B2" value="2102"/>
            <count group_id="B3" value="4202"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.7" spread="8.5"/>
                    <measurement group_id="B2" value="63.6" spread="8.5"/>
                    <measurement group_id="B3" value="63.6" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="639"/>
                    <measurement group_id="B2" value="615"/>
                    <measurement group_id="B3" value="1254"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1461"/>
                    <measurement group_id="B2" value="1487"/>
                    <measurement group_id="B3" value="2948"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin A1C %</title>
          <description>Hemoglobin A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%).</description>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.99" spread="0.86"/>
                    <measurement group_id="B2" value="8.03" spread="0.89"/>
                    <measurement group_id="B3" value="8.01" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Plasma Glucose (FPG)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="184.1" spread="52.2"/>
                    <measurement group_id="B2" value="179.5" spread="45.7"/>
                    <measurement group_id="B3" value="180.4" spread="47.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With MACE-plus (Confirmed Cardiovascular [CV]-Related Death, Nonfatal Myocardial Infarction [MI], Nonfatal Stroke, or Hospitalization Due to Unstable Angina)</title>
        <description>Participants with confirmed MACE-plus events (confirmed cardiovascular, CV-related death, nonfatal myocardial infarction [MI], nonfatal stroke, or hospitalization due to unstable angina). In the MK-3102-018 study, MACE plus events had a data cut-off date of April 15, 2015.</description>
        <time_frame>Up to 156 weeks</time_frame>
        <population>The analysis population included all randomized participants who took at least one dose of blinded study medication and were evaluated for MACE-plus events.</population>
        <group_list>
          <group group_id="O1">
            <title>Omarigliptin 25 mg</title>
            <description>Omarigliptin (MK-3102) 25 mg capsule or tablet administered orally once weekly</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo to omarigliptin capsule or tablet administered once weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With MACE-plus (Confirmed Cardiovascular [CV]-Related Death, Nonfatal Myocardial Infarction [MI], Nonfatal Stroke, or Hospitalization Due to Unstable Angina)</title>
          <description>Participants with confirmed MACE-plus events (confirmed cardiovascular, CV-related death, nonfatal myocardial infarction [MI], nonfatal stroke, or hospitalization due to unstable angina). In the MK-3102-018 study, MACE plus events had a data cut-off date of April 15, 2015.</description>
          <population>The analysis population included all randomized participants who took at least one dose of blinded study medication and were evaluated for MACE-plus events.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2090"/>
                <count group_id="O2" value="2100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66" lower_limit="-1.14" upper_limit="-0.90"/>
                    <measurement group_id="O2" value="70" lower_limit="-1.20" upper_limit="-0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With an Event of MACE (Confirmed CV-Related Death, Fatal and Nonfatal MI, and Fatal and Nonfatal Stroke)</title>
        <description>Participants with an Event of MACE (confirmed cardiovascular, CV-related death, fatal and nonfatal myocardial infarction [MI], and fatal and nonfatal stroke).</description>
        <time_frame>Up to 179 weeks</time_frame>
        <population>The analysis population included all randomized participants who took at least one dose of blinded trial medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Omarigliptin 25 mg</title>
            <description>Omarigliptin (MK-3102) 25 mg capsule or tablet administered orally once weekly</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo to omarigliptin capsule or tablet administered once weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an Event of MACE (Confirmed CV-Related Death, Fatal and Nonfatal MI, and Fatal and Nonfatal Stroke)</title>
          <description>Participants with an Event of MACE (confirmed cardiovascular, CV-related death, fatal and nonfatal myocardial infarction [MI], and fatal and nonfatal stroke).</description>
          <population>The analysis population included all randomized participants who took at least one dose of blinded trial medication.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2092"/>
                <count group_id="O2" value="2100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114" lower_limit="-1.14" upper_limit="-0.90"/>
                    <measurement group_id="O2" value="114" lower_limit="-1.20" upper_limit="-0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With an Event Per 100 Person-Years for First Event of MACE (Confirmed CV-Related Death, Fatal and Nonfatal MI, and Fatal and Nonfatal Stroke)</title>
        <description>Participants with an event of MACE (confirmed cardiovascular, CV-related death, fatal and nonfatal myocardial infarction [MI], and fatal and nonfatal stroke). Person-years were calculated as the sum of all participants′ follow-up time to first event.</description>
        <time_frame>Up to 179 weeks</time_frame>
        <population>The analysis population included all randomized participants who took at least one dose of blinded trial medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Omarigliptin 25 mg</title>
            <description>Omarigliptin (MK-3102) 25 mg capsule or tablet administered orally once weekly</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo to omarigliptin capsule or tablet administered once weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an Event Per 100 Person-Years for First Event of MACE (Confirmed CV-Related Death, Fatal and Nonfatal MI, and Fatal and Nonfatal Stroke)</title>
          <description>Participants with an event of MACE (confirmed cardiovascular, CV-related death, fatal and nonfatal myocardial infarction [MI], and fatal and nonfatal stroke). Person-years were calculated as the sum of all participants′ follow-up time to first event.</description>
          <population>The analysis population included all randomized participants who took at least one dose of blinded trial medication.</population>
          <units>Participants/100 Person-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2092"/>
                <count group_id="O2" value="2100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.96" lower_limit="-1.14" upper_limit="-0.90"/>
                    <measurement group_id="O2" value="2.97" lower_limit="-1.20" upper_limit="-0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>1.29</ci_upper_limit>
            <estimate_desc>Based on the proportional hazards model that includes treatment as an explanatory factor.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hemoglobin A1C (A1C) at Week 18</title>
        <description>A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). This change from baseline reflects the Week 18 A1C minus the Week 0 A1C.</description>
        <time_frame>Baseline and Week 18</time_frame>
        <population>The analysis population consisted of all randomized participants who received at least one dose of blinded study medication and had a baseline or a post-randomization measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Omarigliptin 25 mg</title>
            <description>Omarigliptin (MK-3102) 25 mg capsule or tablet administered orally once weekly</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo to omarigliptin capsule or tablet administered once weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hemoglobin A1C (A1C) at Week 18</title>
          <description>A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). This change from baseline reflects the Week 18 A1C minus the Week 0 A1C.</description>
          <population>The analysis population consisted of all randomized participants who received at least one dose of blinded study medication and had a baseline or a post-randomization measurement.</population>
          <units>Percent</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2092"/>
                <count group_id="O2" value="2100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.58" spread="0.82" lower_limit="-0.62" upper_limit="-0.55"/>
                    <measurement group_id="O2" value="-0.16" spread="0.88" lower_limit="-0.19" upper_limit="-0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in the least squares means</param_type>
            <param_value>-0.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.48</ci_lower_limit>
            <ci_upper_limit>-0.37</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in A1C at Week 18 in a Sub-Study of Participants Taking Insulin (With or Without Metformin)</title>
        <description>A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). This change from baseline reflects the Week 18 A1C minus the Week 0 A1C.</description>
        <time_frame>Baseline and Week 18</time_frame>
        <population>The analysis population consists of all randomized participants in a sub-study of participants taking insulin who received at least one dose of blinded study medication and had a baseline or a post-randomization measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Omarigliptin 25 mg</title>
            <description>Omarigliptin (MK-3102) 25 mg capsule or tablet administered orally once weekly</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo to omarigliptin capsule or tablet administered once weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in A1C at Week 18 in a Sub-Study of Participants Taking Insulin (With or Without Metformin)</title>
          <description>A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). This change from baseline reflects the Week 18 A1C minus the Week 0 A1C.</description>
          <population>The analysis population consists of all randomized participants in a sub-study of participants taking insulin who received at least one dose of blinded study medication and had a baseline or a post-randomization measurement.</population>
          <units>Percentage</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="535"/>
                <count group_id="O2" value="509"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.50" lower_limit="-0.57" upper_limit="-0.42"/>
                    <measurement group_id="O2" value="-0.11" lower_limit="-0.19" upper_limit="-0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Longitudinal data analysis</method>
            <method_desc>Longitudinal data analysis model including terms for treatment, time and the interaction of time by treatment.</method_desc>
            <param_type>Difference in the LS Means vs Placebo</param_type>
            <param_value>-0.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.50</ci_lower_limit>
            <ci_upper_limit>-0.27</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Experienced at Least One Adverse Event in a Sub-study of Participants Taking Insulin Excluding Data After Background Antihyperglycemic Agent (AHA) Change</title>
        <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
        <time_frame>Up to Week 18</time_frame>
        <population>The analysis population included all randomized participants in a sub-study of participants taking insulin who received at least one dose of blinded study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Omarigliptin 25 mg</title>
            <description>Omarigliptin (MK-3102) 25 mg capsule or tablet administered orally once weekly</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo to omarigliptin capsule or tablet administered once weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experienced at Least One Adverse Event in a Sub-study of Participants Taking Insulin Excluding Data After Background Antihyperglycemic Agent (AHA) Change</title>
          <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
          <population>The analysis population included all randomized participants in a sub-study of participants taking insulin who received at least one dose of blinded study medication.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="535"/>
                <count group_id="O2" value="509"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.8"/>
                    <measurement group_id="O2" value="49.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percent vs. Placebo</param_type>
            <param_value>-1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.2</ci_lower_limit>
            <ci_upper_limit>4.9</ci_upper_limit>
            <estimate_desc>Based on Miettinen &amp; Nurminen method. The 95% CI was computed only for those endpoints with at least 4 participants having events in one or more treatment groups.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Discontinued From Study Drug Due to an Adverse Event in a Sub-Study of Participants Taking Insulin Excluding Data After Background AHA Change</title>
        <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
        <time_frame>Up to Week 18</time_frame>
        <population>The analysis population included all randomized participants in a sub-study of participants taking insulin who received at least one dose of blinded study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Omarigliptin 25 mg</title>
            <description>Omarigliptin (MK-3102) 25 mg capsule or tablet administered orally once weekly</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo to omarigliptin capsule or tablet administered once weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Discontinued From Study Drug Due to an Adverse Event in a Sub-Study of Participants Taking Insulin Excluding Data After Background AHA Change</title>
          <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
          <population>The analysis population included all randomized participants in a sub-study of participants taking insulin who received at least one dose of blinded study medication.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="535"/>
                <count group_id="O2" value="509"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="-3.13" upper_limit="-2.25"/>
                    <measurement group_id="O2" value="0.8" lower_limit="-4.18" upper_limit="-3.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percentage vs. Placebo</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>1.7</ci_upper_limit>
            <estimate_desc>Based on Miettinen &amp; Nurminen method. The 95% CI was computed only for those endpoints with at least 4 participants having events in one or more treatment groups.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With an Event of CV-Related Death</title>
        <description>Participants with adjudicated and confirmed AEs of cardiovascular-related death.</description>
        <time_frame>Up to 179 weeks</time_frame>
        <population>The analysis population consisted of all randomized participants who received at least one dose of blinded study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Omarigliptin 25 mg</title>
            <description>Omarigliptin (MK-3102) 25 mg capsule or tablet administered orally once weekly</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo to omarigliptin capsule or tablet administered once weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an Event of CV-Related Death</title>
          <description>Participants with adjudicated and confirmed AEs of cardiovascular-related death.</description>
          <population>The analysis population consisted of all randomized participants who received at least one dose of blinded study medication.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2092"/>
                <count group_id="O2" value="2100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37" lower_limit="-40.04" upper_limit="-31.42"/>
                    <measurement group_id="O2" value="35" lower_limit="-41.21" upper_limit="-32.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With an Event Per 100 Person-Years of CV-Related Death</title>
        <description>Participants with adjudicated and confirmed AEs of cardiovascular-related death. Person-years were calculated as the sum of all participants′ follow-up time to event.</description>
        <time_frame>Up to 179 weeks</time_frame>
        <population>The analysis population consisted of all participants who took at least one dose of blinded study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Omarigliptin 25 mg</title>
            <description>Omarigliptin (MK-3102) 25 mg capsule or tablet administered orally once weekly</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo to omarigliptin capsule or tablet administered once weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an Event Per 100 Person-Years of CV-Related Death</title>
          <description>Participants with adjudicated and confirmed AEs of cardiovascular-related death. Person-years were calculated as the sum of all participants′ follow-up time to event.</description>
          <population>The analysis population consisted of all participants who took at least one dose of blinded study medication.</population>
          <units>Participants/100 person-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2092"/>
                <count group_id="O2" value="2100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.94" lower_limit="-40.04" upper_limit="-31.42"/>
                    <measurement group_id="O2" value="0.89" lower_limit="-41.21" upper_limit="-32.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>1.68</ci_upper_limit>
            <estimate_desc>Based on the proportional hazards model that includes treatment as an explanatory factor.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With an Event of First MI (Fatal and Non-fatal)</title>
        <description>Participants with adjudicated and confirmed AEs of fatal and non-fatal MI.</description>
        <time_frame>Up to 179 weeks</time_frame>
        <population>The analysis population consisted of all participants who took at least one dose of blinded study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Omarigliptin 25 mg</title>
            <description>Omarigliptin (MK-3102) 25 mg capsule or tablet administered orally once weekly</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo to omarigliptin capsule or tablet administered once weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an Event of First MI (Fatal and Non-fatal)</title>
          <description>Participants with adjudicated and confirmed AEs of fatal and non-fatal MI.</description>
          <population>The analysis population consisted of all participants who took at least one dose of blinded study medication.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2092"/>
                <count group_id="O2" value="2100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52" lower_limit="-40.04" upper_limit="-31.42"/>
                    <measurement group_id="O2" value="60" lower_limit="-41.21" upper_limit="-32.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With an Event Per 100 Person-Years of First MI (Fatal and Non-fatal)</title>
        <description>Participants with adjudicated and confirmed AEs of fatal and non-fatal MI. Person-years were calculated as the sum of all participants′ follow-up time to first event.</description>
        <time_frame>Up to 179 weeks</time_frame>
        <population>The analysis population consisted of all participants who took at least one dose of blinded study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Omarigliptin 25 mg</title>
            <description>Omarigliptin (MK-3102) 25 mg capsule or tablet administered orally once weekly</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo to omarigliptin capsule or tablet administered once weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an Event Per 100 Person-Years of First MI (Fatal and Non-fatal)</title>
          <description>Participants with adjudicated and confirmed AEs of fatal and non-fatal MI. Person-years were calculated as the sum of all participants′ follow-up time to first event.</description>
          <population>The analysis population consisted of all participants who took at least one dose of blinded study medication.</population>
          <units>Participants/100 person-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2092"/>
                <count group_id="O2" value="2100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.34" lower_limit="-40.04" upper_limit="-31.42"/>
                    <measurement group_id="O2" value="1.55" lower_limit="-41.21" upper_limit="-32.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.60</ci_lower_limit>
            <ci_upper_limit>1.26</ci_upper_limit>
            <estimate_desc>Based on the proportional hazards model that includes treatment as an explanatory factor.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With an Event of Stroke (Fatal and Non-fatal)</title>
        <description>Participants with adjudicated and confirmed AEs fatal and non-fatal stroke.</description>
        <time_frame>Up to 179 weeks</time_frame>
        <population>The analysis population consisted of all participants who took at least one dose of blinded study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Omarigliptin 25 mg</title>
            <description>Omarigliptin (MK-3102) 25 mg capsule or tablet administered orally once weekly</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo to omarigliptin capsule or tablet administered once weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an Event of Stroke (Fatal and Non-fatal)</title>
          <description>Participants with adjudicated and confirmed AEs fatal and non-fatal stroke.</description>
          <population>The analysis population consisted of all participants who took at least one dose of blinded study medication.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2092"/>
                <count group_id="O2" value="2100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32" lower_limit="-40.04" upper_limit="-31.42"/>
                    <measurement group_id="O2" value="34" lower_limit="-41.21" upper_limit="-32.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With an Event Per 100 Person-Years of First Stroke (Fatal and Non-fatal)</title>
        <description>Participants with adjudicated and confirmed AEs fatal and non-fatal stroke. Person-years were calculated as the sum of all participants′ follow-up time to event.</description>
        <time_frame>Up to 179 weeks</time_frame>
        <population>The analysis population consisted of all participants who took at least one dose of blinded study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Omarigliptin 25 mg</title>
            <description>Omarigliptin (MK-3102) 25 mg capsule or tablet administered orally once weekly</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo to omarigliptin capsule or tablet administered once weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an Event Per 100 Person-Years of First Stroke (Fatal and Non-fatal)</title>
          <description>Participants with adjudicated and confirmed AEs fatal and non-fatal stroke. Person-years were calculated as the sum of all participants′ follow-up time to event.</description>
          <population>The analysis population consisted of all participants who took at least one dose of blinded study medication.</population>
          <units>Participants/100 person-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2092"/>
                <count group_id="O2" value="2100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.82" lower_limit="-40.04" upper_limit="-31.42"/>
                    <measurement group_id="O2" value="0.88" lower_limit="-41.21" upper_limit="-32.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>1.52</ci_upper_limit>
            <estimate_desc>Based on the proportional hazards model that includes treatment as an explanatory factor.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With an Event of All-Cause Death</title>
        <description>All-cause death was death from any cause.</description>
        <time_frame>Up to 179 weeks</time_frame>
        <population>The analysis population included all randomized participants who took at least one dose of blinded trial medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Omarigliptin 25 mg</title>
            <description>Omarigliptin (MK-3102) 25 mg capsule or tablet administered orally once weekly</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo to omarigliptin capsule or tablet administered once weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an Event of All-Cause Death</title>
          <description>All-cause death was death from any cause.</description>
          <population>The analysis population included all randomized participants who took at least one dose of blinded trial medication.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2092"/>
                <count group_id="O2" value="2100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With an Event Per 100 Person-Years of the Event of All-Cause Death</title>
        <description>All-cause death was death for any cause. Person-years were calculated as the sum of all participants′ follow-up time to event.</description>
        <time_frame>Up to 179 weeks</time_frame>
        <population>The analysis population included all randomized participants who took at least one dose of blinded study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Omarigliptin 25 mg</title>
            <description>Omarigliptin (MK-3102) 25 mg capsule or tablet administered orally once weekly</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo to omarigliptin capsule or tablet administered once weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an Event Per 100 Person-Years of the Event of All-Cause Death</title>
          <description>All-cause death was death for any cause. Person-years were calculated as the sum of all participants′ follow-up time to event.</description>
          <population>The analysis population included all randomized participants who took at least one dose of blinded study medication.</population>
          <units>Participants/100 Person-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2092"/>
                <count group_id="O2" value="2100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.63"/>
                    <measurement group_id="O2" value="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.85</ci_upper_limit>
            <estimate_desc>Based on the proportional hazards model that includes treatment as an explanatory factor.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in A1C at Week 142</title>
        <description>A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). This change from baseline reflects the Week 142 A1C minus the Week 0 A1C.</description>
        <time_frame>Baseline and Week 142</time_frame>
        <population>The analysis population consisted of all randomized participants who received at least one dose of blinded study medication and had a baseline or a post-randomization measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Omarigliptin 25 mg</title>
            <description>Omarigliptin (MK-3102) 25 mg capsule or tablet administered orally once weekly</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo to omarigliptin capsule or tablet administered once weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in A1C at Week 142</title>
          <description>A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). This change from baseline reflects the Week 142 A1C minus the Week 0 A1C.</description>
          <population>The analysis population consisted of all randomized participants who received at least one dose of blinded study medication and had a baseline or a post-randomization measurement.</population>
          <units>Percent</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2092"/>
                <count group_id="O2" value="2100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" spread="0.06" lower_limit="-0.47" upper_limit="-0.25"/>
                    <measurement group_id="O2" value="-0.06" spread="1.12" lower_limit="-0.17" upper_limit="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>-0.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.46</ci_lower_limit>
            <ci_upper_limit>-0.14</ci_upper_limit>
            <estimate_desc>Longitudinal Data Analysis (LDA) model including terms for treatment, time, and the interaction of time by treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving a Target A1C &lt;7.0 % (53 mmol/Mol) at 4 Months</title>
        <description>A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%).</description>
        <time_frame>4 months</time_frame>
        <population>Data for this efficacy endpoint was not collected, analyzed or summarized.</population>
        <group_list>
          <group group_id="O1">
            <title>Omarigliptin 25 mg</title>
            <description>Omarigliptin (MK-3102) 25 mg capsule or tablet administered orally once weekly</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo to omarigliptin capsule or tablet administered once weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a Target A1C &lt;7.0 % (53 mmol/Mol) at 4 Months</title>
          <description>A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%).</description>
          <population>Data for this efficacy endpoint was not collected, analyzed or summarized.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose (FPG) at 4 Months</title>
        <description>This change from baseline reflects the Month 4 FPG minus the Week 0 FPG.</description>
        <time_frame>Baseline and 4 months</time_frame>
        <population>Data for this efficacy endpoint was not collected, analyzed or summarized.</population>
        <group_list>
          <group group_id="O1">
            <title>Omarigliptin 25 mg</title>
            <description>Omarigliptin (MK-3102) 25 mg capsule or tablet administered orally once weekly</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo to omarigliptin capsule or tablet administered once weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose (FPG) at 4 Months</title>
          <description>This change from baseline reflects the Month 4 FPG minus the Week 0 FPG.</description>
          <population>Data for this efficacy endpoint was not collected, analyzed or summarized.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Initiation of Long-Term Insulin Therapy in Participants Not Receiving Insulin at Baseline</title>
        <description>Long-term insulin therapy was defined as a continuous period of insulin use of more than 3 months.</description>
        <time_frame>Up to 179 weeks</time_frame>
        <population>Data for this efficacy endpoint was not collected, analyzed or summarized.</population>
        <group_list>
          <group group_id="O1">
            <title>Omarigliptin 25 mg</title>
            <description>Omarigliptin (MK-3102) 25 mg capsule or tablet administered orally once weekly</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo to omarigliptin capsule or tablet administered once weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Initiation of Long-Term Insulin Therapy in Participants Not Receiving Insulin at Baseline</title>
          <description>Long-term insulin therapy was defined as a continuous period of insulin use of more than 3 months.</description>
          <population>Data for this efficacy endpoint was not collected, analyzed or summarized.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Experienced at Least One Adverse Event</title>
        <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
        <time_frame>Up to 234 weeks</time_frame>
        <population>The analysis population included all randomized participants who took at least one dose of blinded study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Omarigliptin 25 mg</title>
            <description>Omarigliptin (MK-3102) 25 mg capsule or tablet administered orally once weekly</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo to omarigliptin capsule or tablet administered once weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experienced at Least One Adverse Event</title>
          <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
          <population>The analysis population included all randomized participants who took at least one dose of blinded study medication.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2092"/>
                <count group_id="O2" value="2100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.3"/>
                    <measurement group_id="O2" value="76.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Discontinued From Study Drug Due to an Adverse Event</title>
        <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
        <time_frame>Up to 212 weeks</time_frame>
        <population>The analysis population included all randomized participants who took at least one dose of blinded study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Omarigliptin 25 mg</title>
            <description>Omarigliptin (MK-3102) 25 mg capsule or tablet administered orally once weekly</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo to omarigliptin capsule or tablet administered once weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Discontinued From Study Drug Due to an Adverse Event</title>
          <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
          <population>The analysis population included all randomized participants who took at least one dose of blinded study medication.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2092"/>
                <count group_id="O2" value="2100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1"/>
                    <measurement group_id="O2" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in FPG at Week 18 in a Sub-Study of Participants Taking Insulin</title>
        <description>This change from baseline reflects the Week 18 FPG minus the Week 0 FPG.</description>
        <time_frame>Baseline and Week 18</time_frame>
        <population>The analysis population consisted of all randomized participants in a sub-study of participants taking insulin who received at least one dose of blinded study medication and had a baseline or a post-randomization measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Omarigliptin 25 mg</title>
            <description>Omarigliptin (MK-3102) 25 mg capsule or tablet administered orally once weekly</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo to omarigliptin capsule or tablet administered once weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in FPG at Week 18 in a Sub-Study of Participants Taking Insulin</title>
          <description>This change from baseline reflects the Week 18 FPG minus the Week 0 FPG.</description>
          <population>The analysis population consisted of all randomized participants in a sub-study of participants taking insulin who received at least one dose of blinded study medication and had a baseline or a post-randomization measurement.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="535"/>
                <count group_id="O2" value="509"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.8" lower_limit="-12.1" upper_limit="-1.5"/>
                    <measurement group_id="O2" value="-3.6" lower_limit="-9.1" upper_limit="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.421</p_value>
            <method>Longitudinal constrained data analysis</method>
            <param_type>Difference in the least squares means</param_type>
            <param_value>-3.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.8</ci_lower_limit>
            <ci_upper_limit>4.5</ci_upper_limit>
            <estimate_desc>Based on a LDA model including terms for treatment, time and the interaction of time by treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving a Target A1C &lt;7.0 % (53 mmol/Mol) at Week 18 in a Sub-Study of Participants Taking Insulin</title>
        <description>A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Analysis was performed with multiple data imputation.</description>
        <time_frame>18 weeks</time_frame>
        <population>The analysis population consisted of all randomized participants in a sub-study of participants taking insulin who received at least one dose of blinded study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Omarigliptin 25 mg</title>
            <description>Omarigliptin (MK-3102) 25 mg capsule or tablet administered orally once weekly</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo to omarigliptin capsule or tablet administered once weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a Target A1C &lt;7.0 % (53 mmol/Mol) at Week 18 in a Sub-Study of Participants Taking Insulin</title>
          <description>A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Analysis was performed with multiple data imputation.</description>
          <population>The analysis population consisted of all randomized participants in a sub-study of participants taking insulin who received at least one dose of blinded study medication.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="535"/>
                <count group_id="O2" value="509"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.0" lower_limit="18.5" upper_limit="26.1"/>
                    <measurement group_id="O2" value="10.2" lower_limit="7.5" upper_limit="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Estimated using standard multiple imputation techniques.</p_value_desc>
            <method>Miettinen &amp; Nurminen method</method>
            <param_type>Between group rate difference</param_type>
            <param_value>11.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.9</ci_lower_limit>
            <ci_upper_limit>16.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With an Event of First Hospitalization for Heart Failure (Exploratory)</title>
        <description>Participants with adjudicated and confirmed events of first hospitalization for heart failure.</description>
        <time_frame>Up to 179 weeks</time_frame>
        <population>The analysis population consisted of all participants who took at least one dose of blinded study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Omarigliptin 25 mg</title>
            <description>Omarigliptin (MK-3102) 25 mg capsule or tablet administered orally once weekly</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo to omarigliptin capsule or tablet administered once weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an Event of First Hospitalization for Heart Failure (Exploratory)</title>
          <description>Participants with adjudicated and confirmed events of first hospitalization for heart failure.</description>
          <population>The analysis population consisted of all participants who took at least one dose of blinded study medication.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2092"/>
                <count group_id="O2" value="2100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With an Event Per 100 Person-years of the Event of the First Hospitalization for Heart Failure (Exploratory)</title>
        <description>Participants with adjudicated and confirmed events of first hospitalization for heart failure. Person-years were calculated as the sum of all participants′ follow-up time to event.</description>
        <time_frame>Up to 179 weeks</time_frame>
        <population>The analysis population consisted of all participants who took at least one dose of blinded study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Omarigliptin 25 mg</title>
            <description>Omarigliptin (MK-3102) 25 mg capsule or tablet administered orally once weekly</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo to omarigliptin capsule or tablet administered once weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an Event Per 100 Person-years of the Event of the First Hospitalization for Heart Failure (Exploratory)</title>
          <description>Participants with adjudicated and confirmed events of first hospitalization for heart failure. Person-years were calculated as the sum of all participants′ follow-up time to event.</description>
          <population>The analysis population consisted of all participants who took at least one dose of blinded study medication.</population>
          <units>Participants/100 Person-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2092"/>
                <count group_id="O2" value="2100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.51"/>
                    <measurement group_id="O2" value="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.35</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
            <estimate_desc>Based on the proportional hazards model that includes treatment as an explanatory factor.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 234 weeks</time_frame>
      <desc>Participants with serious adverse events with an incidence &gt; 0% and with &gt;5% non-serous adverse events in one or more treatment groups during the Treatment Period + Post-Treatment Follow-up including Post-21 days after last dose of blinded study treatment for randomized participants receiving one or more doses of study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Omarigliptin 25 mg</title>
          <description>Omarigliptin (MK-3102) 25 mg capsule or tablet administered orally once weekly</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Matching placebo to omarigliptin capsule or tablet administered once weekly.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="512" subjects_at_risk="2092"/>
                <counts group_id="E2" subjects_affected="503" subjects_at_risk="2100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Agranulocytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="2092"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Coagulation factor deficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Splenic infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Thrombocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2092"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="35" subjects_affected="30" subjects_at_risk="2092"/>
                <counts group_id="E2" events="28" subjects_affected="27" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="29" subjects_affected="27" subjects_at_risk="2092"/>
                <counts group_id="E2" events="36" subjects_affected="31" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="39" subjects_affected="33" subjects_at_risk="2092"/>
                <counts group_id="E2" events="46" subjects_affected="42" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="2092"/>
                <counts group_id="E2" events="17" subjects_affected="16" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="2092"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Bradyarrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Cardiac aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="2092"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="21" subjects_affected="17" subjects_at_risk="2092"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="2092"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="2092"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="2092"/>
                <counts group_id="E2" events="25" subjects_affected="20" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2092"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Conduction disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Cor pulmonale</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="24" subjects_affected="22" subjects_at_risk="2092"/>
                <counts group_id="E2" events="24" subjects_affected="23" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Coronary artery insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2092"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="2092"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="2092"/>
                <counts group_id="E2" events="19" subjects_affected="17" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="2092"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Myocardial reperfusion injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Silent myocardial infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Sinus node dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Ventricular tachyarrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2092"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Trifascicular block</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital claw toe</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Encephalocele</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness neurosensory</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Deafness unilateral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Vestibular disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Keratitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Retinal tear</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Acquired oesophageal web</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Anal spasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Chronic gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Diabetic gastroenteropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Diabetic gastroparesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Enterovesical fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Gastric polyps</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Gastric varices haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Gastroduodenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2092"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Gastrointestinal ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Incarcerated umbilical hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="2092"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Noninfective gingivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Pancreatic cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Pancreatitis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Strangulated umbilical hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Complication associated with device</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="2092"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="2092"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Vascular stent restenosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Catheter site haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Vascular stent thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="2092"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2092"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="2092"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Hepatorenal syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Hydrocholecystis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Abscess intestinal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="2092"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Bronchitis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary aspergillosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary aspergillosis allergic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="2092"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Chronic hepatitis C</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Diabetic foot infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Diabetic gangrene</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Endocarditis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Endophthalmitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Enterococcal sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Febrile infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="2092"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Gas gangrene</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="2092"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>HIV infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Infectious pleural effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of bronchiectasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Klebsiella sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Mediastinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Neuroborreliosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Nosocomial infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Pelvic sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Pneumocystis jirovecii pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="37" subjects_affected="35" subjects_at_risk="2092"/>
                <counts group_id="E2" events="31" subjects_affected="31" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Pneumonia respiratory syncytial viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Pneumonia streptococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Postoperative abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="2092"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Subdural empyema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2092"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Vulval abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Acetabulum fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Avulsion fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Cardiac procedure complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Chemical peritonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2092"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Coronary artery restenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Cystitis radiation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Face injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Flail chest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Gastrointestinal anastomotic leak</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2092"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Incarcerated incisional hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Postoperative ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Procedural haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Soft tissue injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Spinal cord injury cervical</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Stomal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Synovial rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Traumatic haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Vascular graft occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Procedural pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Traumatic intracranial haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Blood sodium decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Diabetic metabolic decompensation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="2092"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="2092"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Amyotrophy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2092"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Gouty arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2092"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Osteitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="2092"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Trigger finger</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma gastric</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="2092"/>
                <counts group_id="E2" events="15" subjects_affected="10" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of eyelid</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Benign renal neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2092"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Bladder cancer recurrent</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Bone cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Breast cancer in situ</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Cholangiocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Colorectal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Hepatic cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Hodgkin's disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Intraductal proliferative breast lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Lung carcinoma cell type unspecified stage IV</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Lung squamous cell carcinoma stage II</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Metastatic gastric cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Neuroendocrine carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma metastatic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Pancreatic neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Parathyroid tumour benign</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="2092"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Prostate cancer stage 0</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Prostate cancer stage II</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Prostatic adenoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2092"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2092"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="2092"/>
                <counts group_id="E2" events="9" subjects_affected="5" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Tonsil cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Urinary tract neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Vocal cord neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Benign ear neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Ear neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Basal ganglia infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Basal ganglia stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Brain stem infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2092"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Cauda equina syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2092"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Cerebral small vessel ischaemic disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="2092"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Cerebrovascular insufficiency</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Cervical radiculopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Dementia Alzheimer's type</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Embolic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Facial paralysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Hypertensive encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>IIIrd nerve paralysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="2092"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Meralgia paraesthetica</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Monoparesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Myelitis transverse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Nerve root compression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="2092"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Thalamic infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Toxic encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="2092"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>VIth nerve paralysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Vascular dementia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device breakage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Device malfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal behaviour</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Acute stress disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2092"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Somatic symptom disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Stress</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Substance-induced mood disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="2092"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Calculus urethral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Haemorrhage urinary tract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="2092"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Stag horn calculus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Ureteric stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Breast fibrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Genital prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Prostatic dysplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Uterine haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2092"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="2092"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2092"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Dermatosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2092"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Dry gangrene</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Extremity necrosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2092"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="2092"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2092"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Iliac artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="17" subjects_affected="14" subjects_at_risk="2092"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Peripheral artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Peripheral artery stenosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2092"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Peripheral artery thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2092"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2092"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="788" subjects_at_risk="2092"/>
                <counts group_id="E2" subjects_affected="794" subjects_at_risk="2100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="167" subjects_affected="123" subjects_at_risk="2092"/>
                <counts group_id="E2" events="195" subjects_affected="145" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="163" subjects_affected="123" subjects_at_risk="2092"/>
                <counts group_id="E2" events="150" subjects_affected="120" subjects_at_risk="2100"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="131" subjects_affected="108" subjects_at_risk="2092"/>
                <counts group_id="E2" events="141" subjects_affected="98" subjects_at_risk="2100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="139" subjects_affected="97" subjects_at_risk="2092"/>
                <counts group_id="E2" events="199" subjects_affected="139" subjects_at_risk="2100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="3990" subjects_affected="530" subjects_at_risk="2092"/>
                <counts group_id="E2" events="3688" subjects_affected="473" subjects_at_risk="2100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

